Scholar Rock Secures $550M Debt Facility From Blue Owl Capital

Why It Matters

The regulatory clearance and robust financing give Scholar Rock a clear path to launch the first muscle‑targeted SMA therapy, unlocking a multi‑billion‑dollar market and diversifying its neuromuscular portfolio.

Key Takeaways

• Upitigramab BLA resubmission slated after FDA reinspection
• New $550M debt facility secures liquidity for launch and R&D
• EMA decision expected mid‑2026, with German launch preparations underway
• Phase 2 OVAL trial dosing infants and toddlers with SMA
• SRK‑439 shows tenfold potency over upitigramab in preclinical data

Pulse Analysis

Scholar Rock’s latest earnings call underscored a pivotal regulatory moment for its lead asset, upitigramab. The FDA completed a field visit to the Catalent, Indiana manufacturing site and issued no further remediation requests, clearing the path for a rapid BLA resubmission. Management reaffirmed its 2026 U.S. approval target, while the European Medicines Agency is slated to render a marketing authorization decision by mid‑year. Securing both U.S. and EU clearances would make upitigramab the first muscle‑targeted therapy for spinal muscular atrophy, addressing a gap left by existing SMN‑focused treatments.

The company’s balance sheet now supports an aggressive commercial rollout. Cash and cash equivalents stood at $368 million at year‑end, bolstered by $60 million of warrant exercises, while a new $550 million senior debt facility provides ample runway for site expansions, specialty‑pharmacy contracts and a 10,000‑nurse home‑infusion network. Scholar Rock estimates the global SMA market at roughly $5 billion, and its early‑stage prescriber outreach aims to capture a sizable share once upitigramab receives approval. The financial flexibility also underwrites continued R&D spending across its anti‑myostatin pipeline.

Beyond upitigramab, Scholar Rock is de‑risking its portfolio with multiple late‑stage programs. The Phase 2 OVAL study continues enrolling infants and toddlers, while the FORGE trial will evaluate upitigramab in facioscapulohumeral muscular dystrophy, a disease affecting over 30,000 patients in the U.S. and Europe. A sub‑cutaneous formulation demonstrated comparable pharmacodynamics to intravenous dosing, opening a more convenient administration route. Meanwhile, SRK‑439, a next‑generation myostatin inhibitor, showed tenfold greater potency in preclinical models and is currently in Phase 1 healthy‑volunteer testing. Success across these assets could expand the company’s addressable market well beyond SMA, positioning Scholar Rock as a leading player in rare neuromuscular therapeutics.

Deal Summary

Scholar Rock Holding Corp announced it has secured a new debt facility of up to $550 million from Blue Owl Capital. The facility includes $100M drawn to refinance existing debt, $100M available for draw in Q1, $150M contingent on FDA approval, and an additional $200M subject to mutual consent. The financing bolsters the company's liquidity for commercial expansion and pipeline development.